22 completed, 9 active not recruiting, 9 unknown, 6 recruiting. 55 Phase 4.
| Phase | Trials | Status |
|---|---|---|
| Phase 4 | 55 | Completed 22, Active not recruiting 9, Unknown 9, Recruiting 6, Not yet recruiting 4, Terminated 3, Suspended 1, Withdrawn 1 |
Follow Denosumab: new trials by email Literature Review of Denosumab trials Research Report on Denosumab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sequential Treatment With Romosozumab Followed by Denosumab vs. Zoledronic Acid for Gains in HIP BMD Romosozumab, Zoledronic Acid 5 MG in 5 ML Injection, Calcium 500 mg and Vitamin D3 800 IU - Osteoporosis in Post-menopausal Women | Phase 4 | Not yet recruiting | Sahlgrenska University Hospital | 216 | 2027-01-11 | 2026-08-19 |
| Romosozumab and Denosumab Combination Therapy for Osteoporosis Romosozumab, Romosozumab and Denosumab - Postmenopausal Osteoporosis | Phase 4 | Not yet recruiting | Massachusetts General Hospital | 100 | 2027-01-01 | 2026-11-03 |
| Romosozumab Versus Denosumab In Glucocorticoid-induced Osteoporosis: An Extended Observation Of a Clinical Trial at 6 Years Romosozumab, Denosumab - Glucocorticoid-Associated Osteopenia and Osteoporosis | Phase 4 | Not yet recruiting | Tuen Mun Hospital | 54 | 2026-09-01 | 2026-08-12 |
| Romosozumab and Denosumab, Alone or Combined, in Postmenopausal Osteoporosis Denosumab, Romosozumab - Osteoporosis | Phase 4 | Recruiting | National Taiwan University Hospital | 90 | 2025-12-03 | 2025-12-16 |
| A Study for the Evaluation of Efficacy and Safety of Prolia® in Participants With Glucocorticoid-induced Osteoporosis in Mainland China Prolia® - Glucocorticoid-induced Osteoporosis | Phase 4 | Active not recruiting | Amgen | 102 | 2025-05-24 | 2026-05-27 |
| Efficacy of Romosozumab and Denosumab Combined Treatment in Postmenopausal Osteoporosis Patients with Multiple Fragility Fractures Romosozumab and Denosumab Combination Therapy, Romosozumab Prefilled Syringe [Evenity], Denosumab (Prolia) - Osteoporosis in Post-menopausal Women | Phase 4 | Not yet recruiting | Marmara University | 60 | 2025-01-15 | 2024-12-27 |
| Romosozumab Versus Denosumab in Glucocorticoid-induced Osteoporosis: an Extended Observation of a Randomized Controlled Trial at 48 Months Romosozumab, Denosumab - Osteoporosis, Glucocorticoids Toxicity | Phase 4 | Completed | Tuen Mun Hospital | 54 | 2024-08-20 | 2026-05-05 |
| Evaluation of Efficacy and Safety of Prolia in Subjects of Male Osteoporosis in Mainland China Prolia - Osteoporosis | Phase 4 | Active not recruiting | Amgen | 102 | 2024-08-06 | 2026-02-12 |
| The Effect of Denosumab on Muscle and Strength and Insulin Sensitivity Denosumab, Saline (0.9% NaCl) - Osteoporosis | Phase 4 | Recruiting | Aarhus University Hospital | 40 | 2024-05-21 | 2025-12-15 |
| RANK-ligand Inhibition to Combat Sarcopenia With Underlying Osteoporosis Denosumab, Zolendronic Acid - Sarcopenia in Elderly | Phase 4 | Recruiting | Prince of Wales Hospital, Shatin, Hong Kong | 120 | 2024-04-09 | 2026-09-18 |
| Effect of Alfacalcidol on Muscle Function in Osteoporosis Patients alfacalcidol, placebo, Denosumab - Sarcopenia | Phase 4 | Unknown | Yonsei University | 340 | 2024-02-13 | 2024-02-22 |
| Preserving Geriatric Muscle With an Osteoporosis Medication Denosumab 60 MG/ML, Zoledronic Acid 5Mg/Bag 100Ml Infusion - Osteoporosis | Phase 4 | Recruiting | Chrissy Kistler | 155 | 2024-02-08 | 2026-09-23 |
| Efficacy and Safety of Combination Denosumab With Eldecalcitol for Postmenopausal Women With Osteoporosis.(ESCORT) Eldecalcitol, Native Vitamin D, Denosumab - Osteoporosis in Postmenopausal Women | Phase 4 | Completed | Xi'an Honghui Hospital | 100 | 2023-08-24 | 2025-11-24 |
| Study of XGEVA® (Denosumab) in Chinese Adults and Skeletally Mature Adolescents With Giant Cell Tumor of the Bone XGEVA® - Giant Cell Tumor of Bone | Phase 4 | Active not recruiting | Amgen | 36 | 2023-08-17 | 2025-10-01 |
| DEnosumab for the Treatment of FIbrous Dysplasia/McCune-Albright Syndrome in Adults (DeFiD) Denosumab 120 Mg/1.7 Ml Inj, Placebo - Fibrous Dysplasia, McCune Albright Syndrome | Phase 4 | Recruiting | Natasha Appelman-Dijkstra | 82 | 2023-06-13 | 2025-01-29 |
| Muscle Impact of Treating Osteoporosis Denosumab, Zoledronic Acid, Denosumab Placebo - Sarcopenia, Osteoporosis | Phase 4 | Completed | Nami Safai Haeri | 20 | 2023-02-14 | 2026-10-27 |
| Effect of Anti-osteoporotic Medications on Nonalcoholic Fatty Liver Disease Denosumab, Alendronate Sodium - Nonalcoholic Fatty Liver, Osteoporosis, Postmenopausal | Phase 4 | Completed | Aristotle University Of Thessaloniki | 72 | 2022-12-23 | 2026-07-23 |
| Effects of Denosumab on Bone Microarchitecture After Total Knee Arthroplasty Denosumab 60 MG/ML Injectable Solution [Prolia], Placebo - Osteoarthritis, Knee | Phase 4 | Unknown | The Affiliated Hospital of Qingdao University | 60 | 2022-10-01 | 2022-09-29 |
| PRevEnting FracturEs in REnal Disease - 1 Denosumab 60 mg/ml, Calcium and vitamin D prophylaxis, Monitoring of post-injection calcium and phosphate - Kidney Diseases, Dialysis; Complications | Phase 4 | Active not recruiting | Western University, Canada | 60 | 2022-06-11 | 2025-05-31 |
| Anabolic Therapy in Postmenopausal Osteoporosis Romosozumab, Denosumab - Postmenopausal Osteoporosis | Phase 4 | Active not recruiting | Massachusetts General Hospital | 50 | 2022-03-24 | 2026-04-15 |
Showing 20 of 55. Sign in to see all of them.
Osteoporosis (27) · Osteoporosis, Postmenopausal (12) · Bone Diseases, Metabolic (4) · Breast Neoplasms (3) · Spinal Cord Injuries (3) · Fractures, Bone (2) · Giant Cell Tumor of Bone (2) · Hyperparathyroidism, Primary (2) · Osteoporotic Fractures (2) · Sarcopenia (2) · Arthralgia (1) · Arthritis, Rheumatoid (1) · Bone Diseases (1) · Bone Resorption (1) · Chronic Kidney Disease-Mineral and Bone Disorder (1)
Massachusetts General Hospital (7) · Amgen (6) · Tuen Mun Hospital (4) · James J. Peters Veterans Affairs Medical Center (3) · Medical University of Vienna (2) · National Taiwan University Hospital (2) · Ottawa Hospital Research Institute (2) · 424 General Military Hospital (1) · Aarhus University Hospital (1) · Aristotle University Of Thessaloniki (1) · Chinese University of Hong Kong (1) · Chrissy Kistler (1) · Columbia University (1) · Eli Lilly and Company (1) · Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau (1)
United States (19) · China (10) · Canada (5) · Poland (3) · Spain (3) · Taiwan (3) · Australia (2) · Austria (2) · Denmark (2) · France (2) · Greece (2) · Hong Kong (2) · South Korea (2) · Sweden (2) · Belgium (1)
Benjamin Leder, MD (3) · Steven C Kirshblum, M.D. (3) · Chi Chiu Mok, MD, FRCP (2) · William A Bauman, M.D. (2) · Antonis Goulas, MD, PhD (1) · Athanasios D Anastasilakis, MD, PhD (1) · Athanasios D Anastasilakis, PhD (1) · Bente Langdahl, MD, Professor, DMSc, PhD (1) · CC Mok (1) · Canan Sanal, Associate Profesor (1) · Changgui Shi, M.D. (1) · Chia-Che Lee (1) · Christian Muschitz, MD (1)
PMID 25761434, PMID 25933031, PMID 26327926, PMID 26666998, PMID 27768831, PMID 29024120, PMID 31127467, PMID 31419313, PMID 31447409, PMID 33386953, PMID 34068083, PMID 34231877, PMID 34568375, PMID 39112628, PMID 39527056, PMID 40760465, PMID 40935429, PMID 41058078, PMID 41621431, PMID 42513484, PMID 42786015
2017 (1), P30AG024827 (1), R01AG052123 (1), R01AR073191 (1), R01DK032333 (1)